A Pipeline in a Product that Reimagines Control of Inflammation

Episode Summary

Executive Summary: Bioegis Therapeutics is developing recombinant human plasma gelsalin, a natural inflammation regulator, as a first-in-class approach for ARDS and other inflammatory diseases. CEO Susan Levinson argues it can dampen cytokine storms and NLRP3-driven inflammation without immunosuppression, with encouraging animal and early human safety data and a broad future pipeline spanning decompression sickness, chronic inflammatory, and neurodegenerative conditions.

Main Topics: Plasma gelsalin biology and mechanism (Priority: 5/5): Levinson explains gelsalin as an endogenous blood protein that regulates inflammation, supports immune defense, and is consumed during severe inflammatory stress; Bioegis aims to replenish it with recombinant protein. ARDS as lead indication (Priority: 5/5): The company is targeting acute respiratory distress syndrome because it is a severe, high-mortality lung injury with no approved drug therapies and a major unmet need in critical care. Non-immunosuppressive anti-inflammatory profile (Priority: 5/5): A core differentiator is that gelsalin appears to reduce harmful inflammation and cytokine storm while preserving the body's ability to fight infection, unlike many anti-inflammatory drugs. Preclinical and clinical development status (Priority: 4/5): Bioegis describes extensive animal-model evidence across multiple disease states and early human safety findings, while ongoing ARDS trials focus on regulatory endpoints such as mortality and ventilation outcomes. Platform and pipeline expansion (Priority: 4/5): Beyond ARDS, Bioegis sees gelsalin as potentially applicable to decompression sickness, chronic inflammatory disease, and possibly neurodegenerative disorders linked to inflammation and aging. Clinical trial and funding strategy (Priority: 3/5): Levinson discusses the operational difficulty of ARDS studies, the use of many global sites, and the importance of non-dilutive funding such as support from BARDA and the U.S. Navy.

Key Arguments: Gelsalin is a normal human protein that helps regulate inflammation rather than causing disease; the problem is inflammatory excess, not absence of the protein. Bioegis licensed the Harvard-originated technology and associated patents, building on work by gelsalin discoverer Thomas Stossel. ARDS is a life-threatening syndrome with major organ and lung injury and no approved pharmaceutical treatment, making it a high-need target. Unlike many anti-inflammatory approaches, gelsalin is presented as non-immunosuppressive and potentially safer for critically ill patients. Animal studies suggest gelsalin improves survival even in severe infection models, supporting its therapeutic promise. The mechanism includes inhibition of the NLRP3 inflammasome and broader suppression of cytokine storm signaling. Bioegis reports human dosing data showing healthy volunteers tolerated gelsalin at levels far above baseline without concerning safety findings. The drug has shown efficacy across more than two dozen animal models involving infection, injury, trauma, metabolic disease, and neurologic disease. The company believes the platform could extend into chronic inflammatory illnesses after human proof of concept in acute indications is established. Non-dilutive funding and partnerships are central to advancing a technically difficult ARDS program through expensive clinical development.

Data Points: ARDS mortality in severe cases: 40% - Levinson cited this as the death rate for the most severe type of ARDS. Human dose escalation: 10-fold above baseline - Healthy volunteers received gelsalin at levels about ten times their normal blood level without concerning safety findings. Number of animal models: More than two dozen - Bioegis says gelsalin has shown efficacy across over 24 animal models spanning multiple disease categories. Clinical sites: Over 70 - The ARDS study is being run across a large global site network to support recruitment and protocol fidelity. Patents licensed from Harvard: Over 40 - The company says Harvard bundled more than 40 patents into the license package at the time of technology transfer. BARDA support: $20 million - Levinson said Bioegis received substantial non-dilutive funding from BARDA to support its ARDS study.

Pivotal Quotes: "It is designed to permit inflammation where it is needed to counter the threats that attack us, such as infection and injury, but to also then quench the fire when it is time to shift from the inflammatory situation into a healing mode." — Susan Levinson: Explaining the normal physiological role of plasma gelsalin. "Gelsalin is quite unique in that we've actually demonstrated that if you give gelsalin in animal models to animals that have been infected with extremely serious infections, it actually improves survival." — Susan Levinson: Describing why the protein may be safer than conventional anti-inflammatory therapies. "The most severe type of ARDS leads to death in 40% of the patients." — Susan Levinson: Framing the clinical urgency of the lead indication.

Implications: If validated in humans, gelsalin could offer a rare anti-inflammatory therapy that does not suppress immunity, potentially changing ARDS care and opening a broad pipeline in acute and chronic inflammatory diseases.